Small-Cell Lung Cancer: The Impower133 And Caspian Trials

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

Discussion of IMpower133 and CASPIAN Trials

Targeted Oncology

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

The CASPIAN Versus IMpower133 Regimen

A Win for Small–Cell Lung Cancer: IMPOWER 133

Dr. Lai on the Results of the CASPIAN Trial in Small Cell Lung Cancer

Extensive-Stage SCLC: Potential in the CASPIAN Trial

Frontline I-O Strategies in SCLC: Practical Implications

IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

Emerging Therapies for Extensive Stage SCLC and CASPIAN Trial

Expert comment: CASPIAN trial of durvalumab in SCLC | Raffaele Califano

Medicine Matters oncology

Dr. Horn on Updated Data From IMpower133 in Small Cell Lung Cancer

I/O + Chemotherapy in Treatment-Naïve ES-SCLC

CASPIAN Trial: Durvalumab and Chemotherapy in ES-SCLC

Small Cell Lung Cancer: Interpreting Data From IMpower133

Chemoimmunotherapy for ES SCLC: CASPIAN Trial

Researcher comment: The KEYNOTE-604 trial | Charles Rudin

Medicine Matters oncology

Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC

IMpower133 in SCLC

Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC